Topics:
Melanoma/Skin Cancer • Medical Oncology
Based on the results of SWOG S1801, neoadjuvant vs adjuvant pembrolizumab for resected stage IIIB-IV melanoma, are you starting to recommend neoadjuvant pembro for your patients?
Answer from: Medical Oncologist at Community Practice
Yes, I now usually would recommend neoadjuvant therapy for melanoma stage 3.
If a clinical trial is open, I prefer to enroll patients in it.
Patients who have contraindications to immunotherapy are treated with surgery first.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree with the above recommendations. If there is a clinical trial for neo-adjuvant therapy, that would be favored. Outside of a clinical trial, neo-adj pembrolizumab is a reasonable approach for this group of patients.